PerkinElmer Acquires Spectral GenomicsMay 2, 2006
The move strengthens the company's capabilities in screening and diagnostics, and its leading-edge molecular karyotyping technology is expected to drive advances in prenatal and neonatal research and disease detection.
BOSTON /BUSINESS WIRE/ -- PerkinElmer, Inc., a global technology leader in health sciences and photonics, announced the acquisition of the assets of Spectral Genomics, Inc., a leader in molecular karyotyping technology, which is used to evaluate chromosomal abnormalities. Terms of the deal were not disclosed.
Spectral Genomics' array products and analysis software help pharmaceutical, biotechnology, cytogenetic, and clinical researchers identify chromosomal abnormalities related to the study of cancer and pre- and post-natal genetic disorders. The company's proprietary Array Comparative Genome Hybridization (CGH) technology provides a high-resolution global view of the human genome, enabling researchers to identify the exact location of any chromosomal deletions and amplifications that can cause an increased risk of genetic disease.
"Spectral Genomics' innovative technologies are highly complementary to our current molecular medicine and genetic screening offerings," said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences. "By enabling rapid surveys of the whole genome at high resolution, scientists can produce abundant, highly reproducible data in a fraction of the time required by standard methods, driving higher productivity in the lab."
Array-based karyotyping is widely expected to replace florescent in-situ hybridization (FISH), G-banding microscopic analysis, and other conventional forms of karyotyping in the cytogenetic market, which was valued at approximately $1.4 billion in 2004. The Array CGH marketplace is also positioned for strong growth as more academic institutions leverage this technology in their biomarker discovery programs.
Health sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.
PerkinElmer, Inc., is a global technology leader driving growth and innovation in health sciences and photonics markets to improve the quality of life. The company reported revenues of $1.5 billion in 2005, has 8,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
Most Read Articles